Log in

NYSE:DGX - Quest Diagnostics Stock Price, Forecast & News

$110.97
+1.04 (+0.95 %)
(As of 02/28/2020 06:00 AM ET)
Today's Range
$108.76
Now: $110.97
$113.25
50-Day Range
$106.19
MA: $110.14
$113.48
52-Week Range
$82.59
Now: $110.97
$113.97
Volume2.10 million shs
Average Volume862,893 shs
Market Capitalization$14.81 billion
P/E Ratio17.67
Dividend Yield1.93%
Beta0.89
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.18 per share
Book Value$42.61 per share

Profitability

Net Income$858 million

Miscellaneous

Employees46,000
Market Cap$14.81 billion
Next Earnings Date4/28/2020 (Estimated)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.


Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Thursday, January 30th. Shareholders of record on Tuesday, April 7th will be paid a dividend of $0.56 per share on Tuesday, April 21st. This represents a $2.24 annualized dividend and a yield of 2.02%. The ex-dividend date is Monday, April 6th. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.53. View Quest Diagnostics' Dividend History.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) released its quarterly earnings results on Thursday, January, 30th. The medical research company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.60 by $0.07. The medical research company earned $1.93 billion during the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a net margin of 11.10% and a return on equity of 16.15%. The firm's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.36 EPS. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of at least $6.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.73. The company issued revenue guidance of $7.80 billion to $7.90 billion, compared to the consensus revenue estimate of $7.89 billion.

What price target have analysts set for DGX?

16 brokerages have issued 1-year target prices for Quest Diagnostics' stock. Their forecasts range from $85.00 to $122.00. On average, they anticipate Quest Diagnostics' share price to reach $108.93 in the next year. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 3 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "In recent times, Quest Diagnostics has been refocusing on its diagnostic information services wing and disciplined capital deployment. Its acquisitions and collaborations with hospitals continue to act as key drivers. We are upbeat about Quest Diagnostics’ Preferred Network partnership with UnitedHealthcare. In the past three months, the company has outperformed its industry. The company exited second-quarter 2019 with better-than-expected earnings as well as revenues On the flip side, the company is currently facing several reimbursement issues. Also, a rise in patient concession along with certain reserve adjustments caused a decline in revenue per requisition. Also, adjusted earnings declined on a year-over-year basis. This apart, escalating costs and a tough competitive landscape are concerns." (9/30/2019)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)

Has Quest Diagnostics been receiving favorable news coverage?

News stories about DGX stock have been trending negative this week, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Quest Diagnostics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Quest Diagnostics.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Honeywell International (HON), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), United Rentals (URI), Accenture (ACN) and AutoZone (AZO).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.93%), Victory Capital Management Inc. (2.99%), Victory Capital Management Inc. (2.96%), Marshall Wace North America L.P. (1.69%), Geode Capital Management LLC (1.62%) and Boston Partners (1.48%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Schroder Investment Management Group, Bank of New York Mellon Corp, FMR LLC, Bank of America Corp DE, Levin Easterly Partners LLC, PGGM Investments and Sei Investments Co.. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Alliancebernstein L.P., Goldman Sachs Group Inc., Lord Abbett & CO. LLC, State Street Corp, Marshall Wace North America L.P., Victory Capital Management Inc. and M&G Investment Management Ltd.. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $110.97.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $14.81 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 46,000 workers across the globe.View Additional Information About Quest Diagnostics.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com/.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  847 (Vote Underperform)
Total Votes:  1,299
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel